nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

Background: The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially, followed by docetaxel at the time of tumor progression. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgensztern, Daniel, Dols, Manuel Cobo, Ponce Aix, Santiago, Postmus, Pieter E., Bennouna, Jaafar, Fischer, Jürgen R., Juan-Vidal, Oscar, Stewart, David J., Ardizzoni, Andrea, Bhore, Rafia, Wolfsteiner, Marianne, Reck, Martin, Talbot, Denis, Govindan, Ramaswamy, Ong, Teng Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906015/
https://www.ncbi.nlm.nih.gov/pubmed/33643895
http://dx.doi.org/10.3389/fonc.2020.569715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906015/
https://www.ncbi.nlm.nih.gov/pubmed/33643895
http://dx.doi.org/10.3389/fonc.2020.569715

Ejemplares similares